Q2 2026 13F · SEC CIK 2013341
Foresite Capital Management VI LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $642.6M
- Reported positions
- 23
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 1.3 yrs
Foresite Capital Management VI LLC is a hedge fund that reported 23 positions worth $642.6M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Cg Oncology Inc (CGON, 26.2%), Alumis Ord (ALMS, 18.6%), Seaport Thereapeutics, Inc. (SPTX, 6.0%).
Foresite Capital Management VI LLC holdings all 23 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| CGONCg Oncology Inc | 26.2% | +6.7% | $168.4M |
| ALMSAlumis Ord | 18.6% | +0.0% | $119.5M |
| SPTXSeaport Thereapeutics, Inc. | 6.0% | — | $38.7M |
| DNLIDenali Therapeutics Inc Com | 5.6% | +15.4% | $35.9M |
| CLDXCelldex Therapeutics Inc New | 5.1% | +178.5% | $32.7M |
| AGIOAgios Pharmaceuticals Inc | 4.5% | +49.5% | $29.1M |
| CRVSCorvus Pharmaceuticals Inc Com | 4.3% | +0.0% | $27.4M |
| PBLSParabilis Medicines, Inc. | 4.3% | — | $27.3M |
| GHRSGh Research PLC | 3.9% | +198.1% | $25.3M |
| 008064206Jade Biosciences Inc | 3.1% | +177.1% | $19.7M |
| HNGEHinge Health, Inc. | 2.8% | +0.0% | $18.3M |
| KYMRKymera Therapeutics Inc | 2.6% | +0.0% | $16.8M |
| ATAIAtaibeckley Inc | 2.3% | +0.0% | $14.5M |
| VSTMVerastem Inc | 1.9% | +0.0% | $12.0M |
| BEAMBeam Therapeutics Inc | 1.8% | — | $11.3M |
| NERVMinerva Neurosciences Inc | 1.7% | -0.1% | $11.0M |
| AVBPArrivent Biopharma Inc | 1.6% | — | $10.5M |
| AURAAura Biosciences Inc | 1.5% | — | $9.5M |
| CRNXCrinetics Pharmaceuticals in | 1.2% | +0.0% | $7.9M |
| RACCResearch Alliance Corp III | 0.5% | — | $3.2M |
| ZURAZura Bio Ltd | 0.4% | +0.0% | $2.7M |
| KLRAKailera Therapeutics Inc | 0.1% | — | $826K |
| IRONDisc Medicine Inc | 0.0% | — | $71K |
What Foresite Capital Management VI LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- SPTX Seaport Thereapeutics, Inc.6.0% of 13F
- PBLS Parabilis Medicines, Inc.4.3% of 13F
- BEAM Beam Therapeutics Inc1.8% of 13F
- AVBP Arrivent Biopharma Inc1.6% of 13F
- AURA Aura Biosciences Inc1.5% of 13F
- RACC Research Alliance Corp III0.5% of 13F
- KLRA Kailera Therapeutics Inc0.1% of 13F
- IRON Disc Medicine Inc0.0% of 13F
Added to
- GHRS Gh Research PLC+198.1% shares
- CLDX Celldex Therapeutics Inc New+178.5% shares
- Jade Biosciences Inc+177.1% shares
- AGIO Agios Pharmaceuticals Inc+49.5% shares
- DNLI Denali Therapeutics Inc Com+15.4% shares
- CGON Cg Oncology Inc+6.7% shares
Reduced
No position shrank by more than 5%.
Sold out
- CNTA Centessa Pharmaceuticals PLCwas 11.8%
- OKUR Onkure Therapeutics Incwas 1.3%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +214.1% /yr
- S&P 500 +20.1%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $642.6M | 23 |
| Q1 2026 | $460.3M | 17 |
| Q4 2025 | $330.8M | 12 |
| Q3 2025 | $258.9M | 12 |
| Q2 2025 | $177.9M | 20 |
| Q1 2025 | $182.5M | 14 |
| Q4 2024 | $224.4M | 14 |
Questions about Foresite Capital Management VI LLC's portfolio
What stocks does Foresite Capital Management VI LLC own?
Foresite Capital Management VI LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 23 positions worth $642.6M. The largest are Cg Oncology Inc (CGON) at 26.2%, Alumis Ord (ALMS) at 18.6%, Seaport Thereapeutics, Inc. (SPTX) at 6.0%, Denali Therapeutics Inc Com (DNLI) at 5.6% and Celldex Therapeutics Inc New (CLDX) at 5.1%.
What did Foresite Capital Management VI LLC buy last quarter?
In Q2 2026, Foresite Capital Management VI LLC added a new position in Seaport Thereapeutics, Inc. (SPTX), a new position in Parabilis Medicines, Inc. (PBLS), a new position in Beam Therapeutics Inc (BEAM), a new position in Arrivent Biopharma Inc (AVBP), a new position in Aura Biosciences Inc (AURA), Gh Research PLC (GHRS) (+198.1% shares), Celldex Therapeutics Inc New (CLDX) (+178.5% shares) and Jade Biosciences Inc (+177.1% shares), compared with its Q1 2026 filing.
What did Foresite Capital Management VI LLC sell last quarter?
In Q2 2026, Foresite Capital Management VI LLC sold all of Centessa Pharmaceuticals PLC (CNTA) and sold all of Onkure Therapeutics Inc (OKUR), compared with its Q1 2026 filing.
When is Foresite Capital Management VI LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Foresite Capital Management VI LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.